Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

February 13, 2019

Tegsedi

Tegsedi (inotersen, Akcea™ Therapeutics)

Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Dosage: 284 mg adminstered by subcutaneous injection 1x weekly

Contraindications

  • Platelet count less than 100 x 109/L (4, 5.1)

  • History of acute glomerulonephritis caused by TEGSEDI

  • Patients with a history of a hypersensitivity reaction to TEGSEDI

Click here for more prescribing information